Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Non-Current Deffered Revenue (2016 - 2025)

Iradimed (IRMD) has disclosed Non-Current Deffered Revenue for 13 consecutive years, with $3.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Non-Current Deffered Revenue rose 30.0% to $3.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $3.6 million, a 30.0% increase, with the full-year FY2024 number at $3.0 million, up 7.15% from a year prior.
  • Non-Current Deffered Revenue was $3.6 million for Q3 2025 at Iradimed, up from $3.3 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $3.6 million in Q3 2025 to a low of $1.4 million in Q4 2022.
  • A 5-year average of $2.5 million and a median of $2.7 million in 2024 define the central range for Non-Current Deffered Revenue.
  • Peak YoY movement for Non-Current Deffered Revenue: fell 29.82% in 2022, then surged 103.14% in 2023.
  • Iradimed's Non-Current Deffered Revenue stood at $1.7 million in 2021, then dropped by 18.11% to $1.4 million in 2022, then soared by 103.14% to $2.8 million in 2023, then increased by 7.15% to $3.0 million in 2024, then increased by 19.36% to $3.6 million in 2025.
  • Per Business Quant, the three most recent readings for IRMD's Non-Current Deffered Revenue are $3.6 million (Q3 2025), $3.3 million (Q2 2025), and $3.2 million (Q1 2025).